Aucentra discovers and develops oral small molecules for a range of cancers. Our pipeline of candidates includes highly potent and selective, first-in-class CDK inhibitors.
Established in 2017, we develop breakthrough classes of drugs to address unmet medical need for some of the most severe cancers. Our novel compounds are more targeted and efficacious than current therapeutics, with less side effects. Aucentra’s deep pipeline of proprietary anti-cancer drugs, developed in partnership with the University of South Australia, includes candidates for the treatment of leukemia, ovarian cancer, glioblastoma, colorectal cancer, breast cancer, prostate cancer, liver cancer and lung cancer.
Company Details
- Employees
- 2
- Founded
- -
- Address
- North Terrace, Adelaide,south Australia 5000,australia
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- aucentra.com
- Keywords
- cancer and therapeutics.
- HQ
- Adelaide, South Australia
Aucentra Therapeutics Questions
Aucentra Therapeutics's website is aucentra.com
Aucentra Therapeutics's LinkedIn profile is https://au.linkedin.com/company/aucentra
Aucentra Therapeutics has
2 employees.
View email and phone details for 2
employees at Aucentra Therapeutics.
Aucentra Therapeutics's industry is
Pharmaceutical Manufacturing
Aucentra Therapeutics's top competitors are
Telix Pharmaceuticals Limited,
Imugene Limited,
Prescient Therapeutics,
Noxopharm Limited,
Carina Biotech,
Haemalogix Ltd,
Immutep Limited,
Myrio Tx,
Ternarx,
Rhythm Biosciences Limited.
Aucentra Therapeutics's categories are Pharmaceutical Manufacturing
Aucentra Therapeutics's founding year is 2017
